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The concept of pharmacologic “class effects” exists across a broad range of medical products
and is particularly pervasive with regard to cardiovascular agents. Evolution of the concept
over the past two decades has shown the influence of physicians’ practice patterns,
pharmaceutical companies, health maintenance organizations and the Food and Drug
Administration (FDA). Understanding the evolution of health care, social and economic
policies, acknowledging the correction of medical misconceptions and inaccurate understand-
ing and appreciating the emergence of new medical knowledge over the past decade should
modify the clinician’s viewpoint of “class effects.” These revelations should signal caution in
extrapolating the outcome efficacy or safety of one agent to another within a pharmacologic
class. The authors urge clinicians, pharmaceutical companies, health maintenance organiza-
tions and the FDA to re-examine their concept of “class effects.” An appeal is made for
physicians to prescribe those pharmaceutical agents with definitive evidence of mortality and
morbidity efficacy and safety established by appropriately scaled randomized clinical
trials. (J Am Coll Cardiol 2002;40:19–26) © 2002 by the American College of Cardiology
Foundation
Over the past two decades, there has evolved a clinical
description applied to pharmacologic agents know as “class
effects.” An early example of the inception of this term was
the antiarrhythmic classification of Vaughn-Williams et al.
(1) to describe the electrophysiologic characteristics of
various antiarrhythmic medications. By grouping antiar-
rhythmic drugs with similar electrophysiologic actions into
classes I to IV, one could crudely generalize the electro-
physiologic mechanisms of various pharmacologic agents (2).
This classification with some limitations nonetheless proved to
be clinically valuable in describing the electrophysiologic effects
of antiarrhythmic agents (3). There was no relationship of the
antiarrhythmic classification to the ultimate outcome benefits
that patients might derive from such therapy.
During the late 1980s and early 1990s, the importance of
neurohumoral stimulation in heart failure (HF) was realized
and led to the development of therapeutic agents that
interfere with the compensatory, but sometimes deleterious,
effects of the renin-angiotensin-aldosterone system. Early
randomized clinical trials in patients with congestive HF
demonstrated the important beneficial hemodynamic
changes associated with angiotensin-converting enzyme
(ACE) inhibitors, called attention to their ventricular re-
modeling properties and documented their benefit in reduc-
ing mortality and morbidity (4). When several randomized
ACE inhibitor clinical trials employing different ACE
inhibitor agents demonstrated similar changes in surrogate
end points and similar mortality and morbidity outcomes,
there emerged an intuitive extrapolation and general con-
clusion that ACE inhibitors possessed a “class effect” that
extended to all ACE inhibitors (5,6). Subsequently, new
ACE inhibitors appeared in the therapeutic marketplace
with a focus on surrogate end points. Whereas physicians
initially believed that all ACE inhibitors were essentially the
same except for varying pharmacologic properties, now, at
the turn of the millennium, scientific knowledge of the
variances of half-life, degree of lipid solubility, route of
elimination, tissue levels and dose-response relationships
indicate that different outcomes may result from specific
ACE inhibitors (7–9). While some ACE inhibitor trials
failed to show benefit, those ACE inhibitors with long
half-lives and tissue penetration resulted in the most im-
pressive clinical data relative to event reduction (7–9).
Nonetheless, caution expressed to the casual acceptance of
“class effects” had little impact on the spread of the broad
medical concept (9,10).
Although the acceptance of “class effects” was promul-
gated by a variety of forces across the health care field, it is
a precarious concept that is fraught with dubious interpre-
tation. It is important for physicians to thoughtfully re-
evaluate the data for “class effects” and reflect on the concept
in light of recent discoveries of incomplete or inaccurate
medical knowledge and new emerging science. These in-
sights have brought forth a new emerging clinical tenet in
the treatment of patients that admonishes “prescribing the
right medication in the right population” (11). These
developments are examined in this manuscript.
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SOCIETAL AND ECONOMIC
INFLUENCE FOR BELIEF IN “CLASS EFFECTS”
Interestingly, several groups within the health care field for
varying reasons quickly adopted the rationale of “class
effects.” Physicians seemed to readily adopt the reasoning of
“class effects” because it certainly made life easier in the
pragmatic daily world of clinical medicine. Not only is it
difficult for a busy clinician to stay abreast of emerging
clinical trials, but, when the early results of randomized
clinical trials seem to indicate similar clinical outcomes for
more than one agent within a drug class, it appeared
reasonable to conclude that the benefits of such agents
extended to all the drugs within that class. Unfortunately,
practicing physicians have been shown to not always be
aware of clinical trial results or appropriate therapeutic
interventions established by evidence-based medicine (12),
and the “lumping together” of clinical trial results by “class
effects” provided a convenient way of understanding new
agents within a pharmacologic class. Occasionally, there
occurred an obstacle to this ideology, as for example with
the Cooperative New Scandinavian Enalapril Survival Study
(CONSENSUS) II (13). After the demonstration of oral
ACE inhibitor therapy rendering mortality benefit in the
CONSENSUS I trial, physicians were surprised to learn
that the administration of intravenous enalapril in the
CONSENSUS II trial resulted in increased mortality and
adverse events in patients with acute myocardial infarction
(AMI) (13). Physician practice patterns reflected a delay in
the early utilization of ACE inhibitors in patients with AMI
as the Consensus II data were examined. Subsequent trial
data analysis of CONSENSUS II concluded that the
adverse events likely resulted from the proischemic effects of
hypotension secondary to the intravenous administration of
enalapril and the possible interaction of age as a confound-
ing factor, which resulted in the increased mortality (13,14).
This conclusion was indirectly reinforced by the beneficial
findings from other orally administered ACE inhibitor trials
in AMI (15,16), and the latter acceptance tended to
entrench the idea that “class effect” outcomes (at least for
oral ACE inhibitors) really existed.
Pharmaceutical companies embraced the concept of “class
effects” for several reasons. Early in the 1990s, companies
with new “me too” pharmaceutical agents that demonstrated
similar properties for surrogate end points began to state
that there was limited value in establishing the outcome
benefit of their specific agent with a randomized clinical trial
because it possessed “class effects” outcome benefits (17).
The Food and Drug Administration (FDA) contributed, in
part, to this strategy by the use of the vaguely defined term
“class labeling.” These attitudinal changes occurred during a
time when medical focus had emerged on the principles of
evidence-based medicine (18). Pharmaceutical companies
were, more often than not, being confronted with the
challenge of performing randomized clinical trials to estab-
lish the efficacy and safety of specific agents. Notwithstand-
ing the immense societal and medical benefits that have
resulted from the pharmaceutical industry at large, it nev-
ertheless is a business entity that seeks to achieve profits and
appease shareholders. With a claim of “class effects” and the
nonperformance of randomized clinical trials, a pharmaceu-
tical company could save a substantial amount of economic
resources and competitive time to the marketplace with
regard to a specific agent. The fact that randomized clinical
trials are expensive, often require prolonged periods of time
to execute and follow outcomes and demand rigor in their
design and execution can pose a daunting burden to a
pharmaceutical company (17). Fortunately for society and
the medical profession, this challenge has been successfully
undertaken by many in the pharmaceutical industry. In
contrast, some pharmaceutical companies resorted to a
marketing strategy of suggesting outcome benefits of their
product based on “class effects” and emphasized the supe-
riority of their product based upon efficacy measured by
changes in specific surrogate end points (e.g., enhanced
blood pressure reduction or cholesterol lowering). Alterna-
tively, they may have demonstrated beneficial changes in
small mechanistic trials directed at new surrogate end points
(e.g., forearm vascular resistance or prostacyclin production)
with a claim of “class effects” to legitimize their product for
outcomes benefit (19). These small mechanistic clinical
trials, which are underpowered to detect morbidity or
mortality outcome evidence, serve to provide a scientific
stage for pharmaceutical agents before the medical commu-
nity at large and create visibility of a new agent in the
marketplace. More often than not, such trials or “marketing
studies” are specifically directed at surrogate end points and
frequently are presented at national scientific symposia to
garner or continue interest in a specific product. Any
negative or adverse data is rarely reported in the literature
due to either the acknowledged influence of publication lag
or bias of negative data (20,21), or, as reported, pharma-
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ceutical sponsors attempt to delay or suppress publication,
forbid it by contractual arrangement or attempt to influence
the nature of the reported findings (22,23). This strategy has
seemingly proved successful because the FDA has previously
approved products based upon an agent’s actions on surro-
gate end points (e.g., some statins or hypertensive agents)
without definitive clinical outcome data (18). Cleverly, this
strategy avoids the possible “down-side” of either the
business goal or the moral dilemma imposed on a pharma-
ceutical company by the discovery of a nonefficacious or
potentially harmful product. What if a specific agent did not
result in beneficial outcomes? What if it was neutral or had
adverse effects? What if its benefit was no greater than that
of a generically available product at a fraction of the cost?
These potential risks are also reflected in the relative
reticence of some pharmaceutical companies to perform
“head-to-head” randomized trials of a new agent against
proven agents of a pharmacologic class for fear of being
shown in any way less efficacious, thereby possibly affecting
their market-share position. It appears that some pharma-
ceutical companies readily adopted the strategy that their
specific drug showed similar changes in surrogate end points
and, thus, inherently was entitled to the associated “class
effect” beneficial outcomes without a need for additional
testing in randomized clinical trials.
Surprisingly, physicians’ practice patterns indicate that
they embraced many of these untested products, apparently
on the merit of a product’s superior action on a specific
surrogate end point or lack of adverse side effects, rational-
izing that its clinical outcome efficacy was established by
“class effects.” Physicians became accustomed to encounter-
ing industry representatives presenting a new FDA ap-
proved medication that had demonstrated enhanced action
against a surrogate end point or was less expensive but had
limited outcomes data of efficacy or safety. Physician’s
practice patterns in prescribing such products thus subse-
quently seemed to endorse and entrench the philosophy of
“class effects.”
Finally, this process in some instances was readily em-
braced by health maintenance organizations (HMO) whose
early primary emphasis was to deliver health care at reduced
costs (24). Through a policy of some HMO formulary
committees focusing on surrogate end points and adopting
a belief in “class effects” (often at the exclusion or lack of
inclusion of knowledgeable medical input), many HMOs
chose the “cost-effective” ACE inhibitor or lipid-lowering
agent of lowest price, rationalizing their putative “class
effect” outcome benefits. Some HMOs were specifically
targeted by industry as seeking the best price while demand-
ing limited data of efficacy and safety. In the current
environment of the new millennium, however, there is a
focus of society and pending congressional legislation di-
rected at HMOs with regard to the patient’s rights, safety
and the quality of care received from such organizations
(25,26). Therefore, we might anticipate that future govern-
ment attention will be focused on what standards are
utilized by HMOs to select pharmaceutical agents for the
benefit of patient care, and the spotlight will focus on
pharmaceutical evidence-based medicine.
EVIDENCE FOR CAUTION IN
INTERPRETING “CLASS EFFECTS”
After a reflective decade of “evidence-based medicine,” what
is a clinician’s perspective on “class effects?” The authors
believe physicians have encountered several aberrations to
the broad medical concept of “class effects” that warrant
thoughtful re-evaluation. The evidence for this viewpoint
emanates from a historical perspective of beta-blockers,
ACE inhibitors and lipid-lowering therapy. Randomized
clinical trials of these pharmacologic agents illustrate how
physician attitudes and practice patterns resulted from: 1)
incomplete or inaccurate medical understanding, or 2) a
failure to appreciate evolving new medical knowledge.
Incomplete or inaccurate medical understanding. The
perplexity of the underutilization of beta-blocker therapy in
cardiovascular disease has been previously detailed by the
authors (27). A major aspect in the past that influenced
physician attitudes concerning beta-blocker therapy was the
widely held false belief that such therapy was contraindi-
cated in patients with congestive HF (27). Although the
Beta-Blocker Heart Attack Trial demonstrated that
propranolol-treated patients with a history of HF received a
47% improved survival from sudden death and a 30%
improved survival for total and cardiovascular mortality,
these data were contrary to accepted medical dictum (28).
There was a prevailing entrenched physician belief that
beta-blocker therapy was deleterious in HF. Over the past
decade, randomized clinical trials have provided substantial
insight to the benefits of beta-blocker therapy, and physi-
cians are increasingly prescribing these valuable agents (29).
Nevertheless, there have been valid exceptions to this
understanding (Table 1). An early obstacle encountered was
the clinical trials of xamoterol, which demonstrated that
beta-blocker agents possessing intrinsic sympathomimetic
properties were deleterious or not beneficial for some
population with HF (30–32). Subsequently, most authori-
tative physicians advised against the use of beta-blocker
agents with intrinsic sympathomimetic activity for patients
with cardiac disease (33), albeit mortality benefit has been
shown for low-dose acebutolol in high-risk AMI patients
(34,35).
A second obstacle arose when the under powered Cardiac
Insufficiency Bisoprolol Study (CIBIS) I trial focused con-
cern and attention on the fact that perhaps beta-blocker
therapy was only beneficial in HF patients with nonisch-
emic heart disease (36). Clinical opinion and speculation
once again fell victim to unreliable “data-dependent” sub-
group analyses of small-scale evidence (37). This concern
was later dispelled when the CIBIS II and Metoprolol
CR/XL Randomized Intervention Trial in Congestive
Heart Failure (MERIT-HF) trials demonstrated unequiv-
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ocal benefit of beta-blocker therapy in more than 6,000
ischemic and nonischemic patients with mild-to-moderate
HF randomized to beta-blocker therapy or placebo (38,39).
Both ischemic and nonischemic beta-blocker-treated pa-
tients received a survival benefit of 30% to 35% from total or
cardiovascular mortality and a 40% to 44% survival benefit
from sudden death (38,39). Thereafter, physicians begin to
“buy-in” to the idea that not only was beta-blocker therapy
beneficial in patients with congestive HF, but perhaps
beta-blockers possessed a “class effect” with the proviso
caveat that this benefit did not extend to agents with
intrinsic sympathomimetic effects. Whereas the specific
agents used in CIBIS II and MERIT-HF employed a
beta1-selective beta-blocker, some investigators proposed,
for theoretical reasons, that newer third-generation nonse-
lective beta-blockers possessing peripheral vascular or alpha-
blocking properties could possibly provide an even greater
degree of efficacy (40–42).
Unfortunately, to the surprise and dismay of both inves-
tigators and the sponsors of the Bucindolol Evaluation
Survival Trial (BEST) performed in 2,708 New York Heart
Association (NYHA) functional class III and IV patients,
essentially minimal or no benefit was found to result from
the third-generation nonselective beta-blocker bucindolol
(43). Additionally, the trial results indicated adverse effects
in black and NYHA functional class IV patients (43–45).
The BEST trial included 627 (23%) black patients who
were randomized and stratified by race, gender, left ventric-
ular ejection fraction and the absence of coronary artery
disease (43). Analysis showed that the lack of mortality
benefit in blacks was not due to a lack of myocardial
functional recovery or neurohormonal response, and the
trend toward increased mortality (p 0.097) was associated
with a significant race-treatment interaction (44). Given
these results, the added pharmaceutical costs of prescribing
a newer third-generation beta-blocker as compared with a
less expensive second-generation beta-blocker employed in
CIBIS II (bisoprolol) or MERIT-HF (metoprolol-XL),
seems to portend the demise of bucindolol in the market-
place. The scientific reasons accounting for the divergent
result of BEST are unknown, but clearly this large-scale
clinical trial exposed physicians’ incomplete medical under-
standing of beta-blocker therapy in patients with HF.
Whereas early speculation centered about bucindolol’s
alpha-blocking properties, which proved deleterious in hy-
pertensive HF patients (46,47), it is difficult to reconcile
that suspicion with the subsequently reported benefit of
carvedilol (also with alpha-blocking properties) in the
Carvedilol Prospective Randomized Cumulative Survival
(COPERNICUS) trial (48). In COPERNICUS, carvedilol-
treated patients with NYHA functional class II to IV HF
had 35% fewer deaths, and this benefit also extended to
black patients (48,49). Speculation arose that carvedilol’s
nonselective beta-blockade and alpha-adrenergic blockade
were particularly advantageous to blacks who have greater
response to cardiac beta2-adrenergic stimuli than whites
(49–51). This explanation, however, fails to explain why
bucindolol with similar pharmacologic properties was non-
efficacious in BEST. A more likely explanation resides in
differences resulting from genetic polymorphisms of en-
zymes responsible for drug metabolism or the adrenergic
receptors themselves, which were responsible for this con-
founding outcome (52,53). The recent appreciation of racial
and pharmacogenetic interaction are also suspected to ac-
count for the findings that blacks received no or limited
benefit in the Study Of Left Ventricular Dysfunction trial
when treated with the ACE inhibitor enalapril (54–56).
Clearly, these enlightening developments highlight our
incomplete knowledge of specific pharmaceutical agents
within a pharmacologic class and engender a cautious
attitude toward the medical generalization of “class effects,”
particularly for outcome efficacy or safety.
Evolving new medical knowledge. As indicated above,
emerging new medical knowledge also encroaches upon the
simplistic vanilla concept of “class effects” as shown from the
randomized clinical trials of various ACE inhibitors. While
early randomized clinical trials of ACE inhibitor drugs
demonstrated similar beneficial outcomes in patients with
left ventricular dysfunction, it was serendipitously discov-
ered that ACE inhibitors also significantly decreased isch-
emic events (57). This surprising discovery (not in concert
with the prevailing view of ACE inhibitors predominantly
Table 1. Beta-Blocker Therapy in Heart Failure*
Beta-Blocker Efficacy Beta-Blocker Adverse Effects
Trial Population
NYHA
Functional
Class Trial Population
NYHA
Functional
Class
MDC (33) 383 I, II, III, IV Xamoterol (30) 516 III, IV
CIBIS I (36) 641 III, IV MEXIS (32) 210 II, III
U.S. Carvedilol (41) 1,094 II, III, IV BEST (43) 2,708 III, IV
CIBIS II (38) 2,647 III, IV
MERIT-HF (39) 3,991 II, III, IV
COPERNICUS (48) 2,289 III, IV
*Modern era of concomitant angiotensin-converting enzyme inhibitors on AII-receptor blockers, diuretics and/or digitalis.
BEST  Bucindolol Evaluation Survival Trial; CIBIS  Cardiac Insufficiency Bisoprolol Study; COPERNICUS 
Carvedilol Prospective Randomized Cumulative Survival trial; MDC  Metoprolol Dilated Cardiomyopathy trial;
MERIT-HF  Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure; MEXIS  Metoprolol and
Xamoterol Infarction Study; NYHA  New York Heart Association.
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affecting hemodynamic changes) was later confirmed in
other randomized clinical trials (58,57). These events led to
an appreciation of the tissue effects of ACE inhibitors.
Subsequent investigations discovered new knowledge of the
role of ACE inhibitors in tissue, their actions on inflam-
matory mediators and a variety of positive effects on the
vascular endothelium (59–61). Clinical recognition that
some ACE inhibitors seem to render benefit against sudden
death while others did not (62), the finding that trandolapril
reduced the incidence of atrial fibrillation (63) and the
finding that ramipril in the Heart Outcomes Prevention
Evaluation trial (64) provided primary and secondary pre-
ventive benefits to a diverse group of patients without
evidence of HF or systolic dysfunction seems to highlight
the variable effects of ACE inhibitors. The putative mech-
anisms that may account for these diverse actions are
unknown but are directed towards the varying effects of
specific ACE inhibitors in tissue and the vascular endothe-
lium (7,64,65). Thus, while ACE inhibitors may share
similar hemodynamic effects and clinical outcomes in pa-
tients with left ventricular systolic dysfunction, their tissue
properties vary substantially. Differences in beneficial out-
comes in populations with arrhythmias (62,63), suspected
diastolic dysfunction (64) and diabetes (64) argue for a
closer examination of the “class effect” concept. All ACE
inhibitors are not the same (9,10).
The past decade has also witnessed an evolution of
medical knowledge concerning vascular atherosclerosis and
plaque rupture and the genetic and biochemical heteroge-
neity that exists in patients with coronary artery disease.
Current medical knowledge has focused scientific attention
on the interactive role of pharmacologic agents, especially
the HMG-Coenzyme A reductase inhibitors (statins) and
the multiple mechanisms of the atherosclerotic plaque and
endothelial substrate (66,67). The role of specific statins on
nitric oxide biosynthesis (68), smooth muscle cell synthesis
of extracellular matrix and apoptosis (69–72), cytokine
production by mononuclear cells (73), tissue factor biosyn-
thesis (74) and perhaps other molecular and cellular mech-
anisms that stabilize plaque have come to the forefront.
These mechanisms present a rationale for the resulting
endothelial nitrous oxide-mediated vasodilation, anti-
inflammatory and antithrombotic effects observed with
statin therapy. These nonlipid mechanisms may be of great
importance, especially in subjects prone to plaque rupture
(66,67). However, new evidence has emerged that statins
may differ substantially in their effects on liver metabolism
(75), collagen production by smooth muscle cells (76,77),
skeletal myolysis (78) and major histocompatibility
complex-II-mediated T-cell activation or immunomodula-
tion (79). Noteworthy in this regard has been the recent
product withdrawal of cerivastatin from the marketplace,
which was prompted by 52 deaths associated with rhabdo-
myolysis (80). In recently reported FDA data of statins (81),
cerivastatin demonstrated an 80-fold increase of adverse
events in comparison with other statins.
Previous pharmacogenetic data have defined that a pa-
tient’s response to a drug may depend on one or more
factors that vary according to the genetic alleles that an
individual carries (11). Factors involved include drug ab-
sorption, drug distribution, drug metabolism and elimina-
tion, drug concentration at the target site and the number
and morphology of target receptors (11). This data also
corroborates reports of efficacy in patients with coronary
artery disease whose outcomes for a specific statin therapy
were correlated with gene variants involved in the drug’s
mode of action (81– 84). Therefore, pathophysiologic
mechanisms relative to atherosclerosis and its therapy have
revealed themselves to be multifactorial and multidimen-
sional and represent evolving new knowledge that was
unanticipated.
Interestingly, these discoveries of complexity have not
overridden the dominant practitioner’s concept that all
statins are the same and share “class effects” outcome
benefits. Despite the more than 40,000 patients randomized
to clinical trials of simvastatin (85), pravastatin (86–88) and
lovastatin (89), which demonstrated significant benefits in
reducing mortality and morbidity, the most commonly
prescribed statin currently in the U.S. is atorvastatin without
such clear evidence of benefit (90–92). Atorvastatin has
recently been shown in the Myocardial Ischemia Reduction
with Aggressive Cholesterol Lowering (MIRACL) trial
(92) that examined 3,086 patients with unstable angina
pectoris or non–Q-wave myocardial infarction to be mainly
beneficial for worsening angina with evidence of ischemia.
Hard end points of death, nonfatal myocardial infarction or
resuscitated cardiac arrest only showed nonsignificant trends
favoring atorvastatin (92). Moreover, atorvastatin did not
affect coronary events during the initial five weeks (which
comprised 70% of total events), HF or the need for
revascularization. Although atorvastatin did reduce the rate
of nonfatal stroke (an uncommon event in the trial), the
positive findings of MIRACL have been criticized as being
far from definitive (93). Reflection upon the existing pre-
scription popularity of atorvastatin without substantive out-
come evidence of broad efficacy is testimony, in part, to the
establishment of the surrogate low-density lipoprotein cho-
lesterol therapeutic target, the power of marketing and the
“class effects” concept and a disappointing commentary to
physicians’ practice patterns in prescribing medications
based on evidence-based randomized clinical trials. These
developments encourage the viewpoint that physicians
should prescribe specific drugs used in clinical trials, at the
target dosage, in a similarly defined population of patients,
to obtain similar clinical outcome benefits (11). This rec-
ommendation is obviously counterintuitive to the broad
concept of “class effects.”
INTERPRETATION WITHOUT LARGE-SCALE EVIDENCE
The authors would be remiss if they did not indicate that
the class divergence discussed (adverse or beneficial) ema-
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nates from differences that sometimes are based on a
relatively small number of events or populations relative to
the size of the overall main clinical trials of a class of
pharmacologic agents (37). Such may be the case for
xamoterol, bucindololol, trandolapril or atorvastatin as dis-
cussed above. Even highly significant differences based on a
relatively small number of events from selected clinical trials
may prove unreliable evidence of the existence of any real
difference (37,94). Besides the element of chance, important
trial differences in study populations, outcome definitions
and dosages employed could have accounted for differences
in observed clinical outcomes. However, when one reflects
on the xamoterol, bucindolol or cerivastatin experience, in a
pragmatic sense, it seems highly unlikely that the respective
pharmaceutical companies will pursue continued investiga-
tion of those agents. In contrast, it might be hoped in a
“perfect world” that pharmaceutical companies would ex-
amine their data to determine if their specific product in a
pharmacologic class is associated with unanticipated adverse
or beneficial effects encountered in the class, for example,
race-interaction, rhabdomyolysis or antiarrhythmic benefit.
In the “real world,” however, once an agent has received
regulatory approval from the FDA and enters the market-
place, additional clinical trials exploring either adverse or
beneficial divergence seem to be seldom undertaken.
CONCLUSIONS AND RECOMMENDATIONS
Understanding the evolution of medical, social and eco-
nomic policies, acknowledging the correction of medical
misconceptions and inaccurate understanding and appreci-
ating the emergence of new medical knowledge over the
past decade should modify the clinician’s viewpoint of “class
effects.” These revelations should signal caution in extrap-
olating the outcome efficacy or safety of one agent to
another within a pharmacologic class (8–11). Nevertheless,
many pharmaceutical agents share similar clinical structures
and physiologic actions on surrogate end points and, there-
fore, categorically reside in a specific pharmaceutical class.
While it is of practical merit to conceptualize that drugs
within a pharmacologic class may result in some similar
physiological actions, experience has shown that evidence-
based morbidity and mortality outcomes in disease popula-
tions may differ widely for agents within a class. Therefore,
the authors urge clinicians, pharmaceutical companies,
HMOs and the FDA to re-examine their concept of “class
effects.” An appeal is made for physicians’ to prescribe those
agents with definitive evidence of mortality and morbidity
efficacy and safety established by appropriately scaled ran-
domized clinical trials (10,11,18,37,94). Pharmaceutical
companies should be encouraged to perform comparative
(head-to-head) trials through policies of the FDA designed
to limit the number of “me too” drugs, and HMOs should
develop cost-effective pharmaceutical policies that incorpo-
rate the evidence of randomized clinical trials. Finally, the
boundaries of “class effects” have not been clearly delineated.
Although emerging knowledge may provide new insights
regarding the generalization of outcome benefits, currently
there is clear evidence that acceptance of the broad medical
“class effect” concept is unwarranted. Like most complex
issues, it probably is not an “all or none” concept but one
that needs careful clarification. Recent editorial attention
has indicated the susceptibility of physicians to “Faustian
bargains” (95) hopefully “class effects” will not be one of
them.
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